Novartis acquires IFM

Novartis International AG, the Switzerland based multinational pharmaceutical corporation, has exercised an option for the acquisition of all outstanding capital stock of IFM Due, Inc., a US based biopharmaceutical company developing small-molecule, orally available drug candidates targeting aberrant inflammatory responses, from IFM Therapeutics, LLC, the US based pharmaceutical company focused on developing biological treatments for autoimmune diseases, for a total consideration of USD 835m, consisting of USD 90m in upfront payment and USD 745m in milestone payments. The strategic acquisition will grant Novartis the complete rights to IFM Due’s portfolio of STING antagonists, which address a range of serious inflammation-driven diseases.

Bridgepoint Advisers has agreed to acquire Alpha FMC

Bridgepoint Group Limited, the UK based private equity firm, through its UK based indirect subsidiary Actium Bidco (UK) Limited, has …

Read More →

Bridgepoint Advisers to make an offer for Alpha Financial

Bridgepoint Group Limited, the UK based private equity firm, through its UK based indirect subsidiary Actium Bidco (UK) Limited, has …

Read More →

Wakeo acquires Veroo Software

Wakeo, the France based provider of a SaaS platform providing real-time visibility on international transport flows (sea, air, road) to …

Read More →

Bregal Unternehmerkapital to acquire a majority stake in Relatech S.p.A.

Bregal Unternehmerkapital GmbH, the Germany based private equity firm, through Gemini BidCo, a special purpose vehicle indirectly controlled by the …

Read More →

DeepForm raises GBP 2m

DeepForm Limited, the UK based company, that specializes in developing and offering novel press tool designs, which help reduce material …

Read More →

PINOVA Capital invests in NEUROMEDEX

Neuromedex, the Germany based provider of disposable products for neurosurgery and intensive care, has been acquired by Pinova Capital GmbH, …

Read More →
close-link
close-link